Q-omics provides the consensus-scored POLR1B profile across patient tissues and cancer cell-line models. POLR1B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, POLR1B is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, POLR1B protein abundance shows 26,924 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, COAD, and HNSC as cancer lineages where POLR1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR1B survival associations across molecular data types. POLR1B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR1B RNA expression–survival associations across cancer types. High POLR1B expression shows unfavorable associations in KIRP, UCEC, KICH, LIHC and CESC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for POLR1B RNA expression.
This table summarizes POLR1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR1B shows lower tumor expression in THCA and higher tumor expression in COAD, BLCA, LUAD, STAD and LUSC. The COAD box plot shows higher POLR1B RNA expression in tumor versus normal tissue (log2 FC = +1.367, t-test p < 0.001).
This table shows molecular features associated with POLR1B in patient tissues and cancer cell lines. In patient samples, POLR1B shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
